

AMENDMENTS TO THE CLAIMS:

Applicants request that the Examiner not enter the amendments filed on October 20, 2003. This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A [~~An injectable~~] composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

- (a) an osteogenic protein; and
- (b) an injectable hyaluronic acid ester,

wherein said admixture is injectable through the skin of the patient.

2. (original) The composition of claim 1 further comprising tricalcium phosphate.

3. (previously presented) The composition of claim 1 further comprising a pore-forming agent wherein said pore-forming agent promotes in situ pore formation following injection of said composition.

4. (original) The composition of claim 1 wherein the osteogenic protein is selected from the group consisting of members of the BMP family.

5. (original) The composition of claim 4 wherein the osteogenic protein is BMP-2.

6. (original) The composition of claim 4 wherein the osteogenic protein is OP-1.

7. (currently amended) A [~~An injectable~~] composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

- (a) BMP-2;
- (b) an injectable hyaluronic acid ester,

wherein the admixture is injectable through the skin of the patient.

8-10. (canceled)

11. (previously presented) The composition of claim 2 further comprising a pore-forming agent wherein said pore-forming agent promotes in situ pore formation following injection of said composition.

12. (new) The composition of claim 1, wherein the hyaluronic acid ester is solubilized in an organic solvent.

13. (new) The composition of claim 1, wherein the hyaluronic acid ester is solubilized in an aqueous solvent.

14. (new) The composition of claim 1, wherein the hyaluronic acid ester is Hyaff11p65.

15. (new) A composition for delivery of osteogenic proteins to a patient comprising a pharmaceutically acceptable admixture comprising

(a) BMP-12;

(b) an injectable hyaluronic acid ester,

wherein the admixture is injectable through the skin of the patient.

16. (new) The composition of claim 15, wherein the hyaluronic acid ester is Hyaff11p65.